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ABSTRACT 
Nanosuspensions are colloidal dispersions and biphasic system consisting of drug particles dispersed in an aqueous vehicle in which 
the diameter of the suspended particle is less than 1μm in size. Many drugs including antibiotics are having poor solubility. 
Nanosuspensions have proven to be a better alternative over other approaches currently available for improving bioavailability of 
such drugs with low solubility. This review describes the methods of pharmaceutical nanosuspension of antibiotic formulations and 
pharmaceutical applications in drug delivery. 
Keywords: Nanosuspension, Bioavailability, Solubility 
 
Article Info 
Received 19 Feb 2017; Review Completed 06 March 2017; Accepted 15 March 2017, Available online 15 March 2017 
Cite this article as: 
Mathew M, Krishnakumar K, Dineshkumar B, Nair SK, Antibiotics Nanosuspension: A Review, Journal of Drug Delivery and 
Therapeutics. 2017; 7(2):128-131            DOI: http://dx.doi.org/10.22270/jddt.v7i2.1406  
*Address for Correspondence  
Merin Mathew, Dept. of Pharmaceutics, St James College of Pharmaceutical Sciences, Chalakudy, Kerala 
Email: stjamespharmacyproject@gmail.com 
 
 
INTRODUCTION 
 Nanotechnology is likely to make a big change in our 
lives, in general, and health scenario, in particular. It is 
one of the most important research and development 
area in today’s era. Nanotechnology is an applicable 
aspect of a broader area of nanoscience which is one of 
the upcoming and highly challenging as well as 
rewarding key research area in the modern scientific set 
up 
1
. It is the science of small particle having unique 
properties, which change on altering the size of the 
particle 
2
. Nanosuspensions are colloidal dispersions and 
biphasic system consisting of drug particles dispersed in 
an aqueous vehicle in which the diameter of the 
suspended particle is less than 1μm in size. Reduction of 
drug particles to nanometer range leads to an enhanced 
dissolution rate due to increased surface area and 
saturation solubility
3
. A nanosuspension not only solves 
the problem of poor solubility and bioavailability but 
also alters the pharmacokinetics of drug and improves 
the drug safety and efficacy. Nanosuspension has been 
reported to enhance absorption and bioavailability. 
IMPORTANCE OF ANTIBIOTICS AS 
NANOSUSPENSION 
Antibiotics also called anti-bacterial are a type of 
antimicrobial
 
drug used in the treatment and prevention 
of bacterial infections. They may either kill or inhibit the 
growth of bacteria. Many antibiotics such as 
Ciprofloxacin, Sulfadiazine, belong to BCS class II/IV, 
having poor solubility and dissolution rate. Nanosizing 
of such drugs leads to a drastic increase in their oral 
absorption and consequently bioavailability. The 
increase in bioavailability is due to increased surface 
area of the particles, increased saturation solubility and 
increase in dissolution velocity. The drug dose reduction 
is possible with enhancement in bioavailability making 
therapy cost effective and in preventing toxicity
4
. 
Formation of nanoparticles could provide some benefits 
such as increased saturation solubility and drug 
dissolution rate, improved bioavailability and dose 
proportionality, and inter-subject variability in 
comparison with the coarse or micronized drug powder.
5
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METHODS OF PREPARATION
6-13
 
Preparation of nanosuspension is reported to be simpler 
and cost effective.  It is particularly for poorly soluble 
drugs and to yield a physically more stable product. For 
manufacturing nanosuspensions, there are two methods, 
“Top-down process technology” and “Bottom-up 
process technology”.  
The top -down process includes:- 
 High pressure homogenization  
 Media milling (Nanocrystals).  
Bottom-up process includes:-  
 Solvent- Antisolvent method  
 Super critical fluid process  
 Emulsification Solvent evaporation technique  
 Lipid emulsion/Micro-emulsion template.  
The principle techniques used in recent years for 
preparing nanosuspensions are: 
1. High pressure homogenization:  
It is most widely used method for preparing 
nanosuspensions of many poorly aqueous soluble drugs . 
It involves three steps. First,the drug powders are 
dispersed in stabilizer solution to form pre-suspension, 
and then the pre-suspension is homogenized in high 
pressure homogenizer at a low pressure for pre-milling, 
and finally homogenized at high pressure for 10 to 25 
cycles until the nanosuspensions of desired size are 
formed.  
2. Milling techniques: 
a) Media Milling:  
This method was first developed and reported by 
Liversidge (1992). The nanosuspensions by this method 
are prepared by high shear media mill. The milling 
chamber is charged with the milling media, water, drug 
and stabilizer and rotated at a very high shear rate under 
controlled temperature for atleast 2-7 days. The milling 
medium is composed of glass, Zirconium oxide or 
highly cross linked polystyrene resin. The high energy 
shear forces are formed as a result of impaction of 
milling media with the drug which results in breaking of 
drug microparticles to nanosized particles.   
b) Dry-Co-grinding:  
Recently many nanosuspensions are prepared by dry 
milling technique. Dry- co-grinding can be carried out 
easily and economically and can be conducted without 
organic solvents. Physicochemical properties and 
dissolution of poorly water soluble drugs are improved 
by Co-grinding because of the improvement in the 
surface polarity and transformation from a crystalline to 
an amorphous drug. 
3. Emulsification-solvent evaporation technique  
This technique involves preparing a solution of drug 
followed by its emulsification in another liquid that is a 
nonsolvent for the drug. Evaporation of the solvent leads 
to precipitation of the drug. Crystal growth and particle 
aggregation can be controlled by creating high shear 
forces using a high-speed stirrer.  
4. Precipitation method 
Within the last decade, precipitation has been applied to 
prepare submicron particles, especially for the poorly 
soluble drugs. The drug is first dissolved in a solvent, 
then this solution is mixed with a miscible anti-solvent 
in the presence of surfactants. Rapid addition of a drug 
solution to the anti-solvent leads to sudden super 
saturation of drug and formation of ultrafine crystalline 
or amorphous drug solids.  
5. Supercritical fluid process  
The particle size reduction was achieved more by the 
solubilisation and nanosizing technologies through the 
super critical fluid process. Super critical fluids (SCF) 
are non-condensable dense fluids whose temperature and 
pressure are greater than its critical temperature (Tc) and 
critical pressure (Tp). This process allows the 
micronization of drug particles to a submicron level. 
Recent advances in SCF process are to create 
nanoparticulate suspension of particle size of 5 to 
2000nm in diameter.   
6. Melt emulsification method  
In this method drug is dispersed in the aqueous solution 
of stabilizer and heated above the melting point of the 
drug and homogenized to give an emulsion. During this 
process, the sample holder will be enwrapped with a 
heating tape fitted with temperature controller and the 
temperature of emulsion will be maintained above the 
melting point of the drug. The emulsion is then cooled 
down either slowly to room temperature or in an 
ice‐bath.  
7. Lipid emulsion/microemulsion template:  
This method is mostly applicable for drugs that are 
soluble in either volatile organic solvents or partially 
water miscible solvents. In this method, the drug is 
dissolved in suitable organic solvent and then emulsified 
in an aqueous phase using suitable surfactants. Then the 
organic solvent is slowly evaporated under reduced 
pressure to form drug particles precipitating in the 
aqueous phase forming the aqueous suspension of the 
drug in the required particle size. Then the suspension 
formed can be suitably diluted to get nanosuspensions. 
Moreover, microemulsions as templates can produce 
nanosuspensions. Microemulsions are thermodynamic-
cally stable and isotropically clear dispersions of two 
immiscible liquids such as oil and water stabilized by an 
interfacial film of surfactant and co-surfactant. The drug 
can be either loaded into the internal phase or the pre-
formed microemulsion can be saturated with the drug by 
intimate mixing. Suitable dilution of the microemulsion 
yields the drug nanosuspension.  
8. Solvent evaporation:  
In the solvent evaporation method, the solutions of 
polymer are prepared in volatile solvents and emulsions. 
The emulsion is converted into a nanoparticle 
suspension on evaporation of the solvent for the 
polymer, which is allowed to diffuse through the 
continuous phase of the emulsion. In the conventional 
methods, two main strategies are being used for the 
formation of emulsions, the preparation of single-
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emulsions, e.g., oil-in-water (o/w) or double-emulsions, 
e.g., (water-in-oil)-in-water, (w/o)/w. These methods 
require high-speed homogenization or ultrasonication, 
followed by evaporation of the solvent, either by 
continuous magnetic stirring at room temperature or 
under reduced pressure. By ultracentrifugation the 
solidified nanoparticles are collected which is washed 
with distilled water to remove the additives like 
surfactants, and then it is lyophilized. The particle size is 
influenced by the concentration of polymer, stabilizer 
and the speed of homogenizer. 
 
Table 1: Summary of the nanosuspension formation technologies [14,15] 
Technology Advantages Disadvantages Drugs 
 
 Precipitation 
 Equipment cost is low 
 Ease of scale up 
 Drug has to be soluble in atleast one 
solvent 
Carbamazepine
16
 
Cyclosporine
17
 
 
 
 
 High Pressure 
 Homogenisation 
  Applicable to most drugs 
 Simple technique with aseptic 
production possible 
  Risk of product 
Contamination is low 
 Prerequisite for drug to be in micronized 
state and suspension formation  before 
homogenization 
 
 
Amphotericin B 
18
 
Azithromycin 
19
 
Budesonide 
20
 
Clofazamine 
21
 
Fenofibrate 
22
 
Ibuprofen 
23
 
Itraconazole 
24
 
 Emulsion / 
Microemulsion 
 High drug solubilisation 
Long shelf life 
 Use of hazardous solvent and  high 
amount of surfactant and stabilizers 
Mutotane
25
 
Griseofulvin 
26
 
 Media Milling  Ease of scale up 
 Batch to batch variation is little 
 High flexibility in handling of  large 
quantities of drugs 
 Generation of residue of milling media 
 It requires milling process from hrs to 
days. 
Cilostazol 
27
 
Danazol 
28
 
Naproxen 
29
 
 
 Dry  Co-Grinding 
 Easy process 
 No organic solvent is needed 
 It requires short grinding time 
 There is generation of residue of milling 
media 
Clarithromycin 
30
 
Glibenclamide 
31
 
 
 
APPLICATIONS 
32-34
 
 Oral administration 
Nanosizing of drugs leads to an increased oral absorption 
and subsequent bioavailability. Improved bioavailability is 
due to the adhesiveness of drug nanoparticles to the mucosa 
and  the increased saturation solubility leading to an 
increased concentration gradient between gastrointestinal 
tract lumen and blood. Aqueous nanosuspensions can be 
used directly in a liquid dosage form and a dry dosage form 
such as tablet or hard gelatin capsule with pellets.  
Granulates can also be produced by spray drying of 
nanosuspensions. 
 Ophthalmic drug delivery 
Nanosuspensions have been providing to be vital for drugs 
that exhibit poor solubility in lachrymal fluids. Suspensions 
offer advantages such as prolonged residence time , which 
is desirable for most ocular diseases for effective treatment 
and avoidance of high tonicity created by water soluble 
drugs. Their actual performance depends on the intrinsic 
solubility of the drug in lachrymal fluids. Thus the intrinsic 
dissolution rate of the drug in lachrymal fluids governs its 
release and ocular bioavailability.  
 Intravenous administration 
Parenteral route of administration provides a quick onset of 
action, rapid targeting and reduced dosage of the drug. It is 
the preferred route for drugs undergoing first-pass 
metabolism and those that are not absorbed in the GIT or 
that get degraded in the GIT. One of the important 
applications of nanosuspension technology is the 
formulation of intravenously administered products. IV 
administration results in several advantages, such as 
administration of poorly soluble drugs without using a 
higher concentration of toxic cosolvents, improving the 
therapeutic effect of the drug available as conventional oral 
formulations and targeting the drug to macrophages and the 
pathogenic microorganisms residing in the macrophages. 
 Targeted drug delivery 
Nanosuspensions can also be used for targeted delivery as 
their surface properties and in vivo behaviour can easily be 
altered by changing either the stabilizer or the milieu. Their 
versatility, ease of scale up and commercial product has 
helped in developing commercial viable nanosuspensions 
for targeted delivery.  
 Pulmonary administration 
Aqueous nanosuspensions can be nebulized using 
mechanical or ultrasonic nebulizers for delivery of the drug 
into lungs. Because of their small size, it is likely that in 
each aerosol droplet at least one drug particle is contained, 
leading to a more uniform distribution of the drug in lungs. 
They also increase adhesiveness and thus cause a 
prolonged residence time. Budenoside drug nanoparticles 
were successfully nebulized using an ultrasonic nebulizer.  
 Mucoadhesion of the nanoparticles 
Nanoparticles orally administered in the form of a 
suspension diffuse into the liquid media and rapidly 
encounter the mucosal surface. The particles are 
immobilized at the intestinal surface by an adhesion 
mechanism referred to as "bioadhesion". Then , the 
concentrated suspension acts as a reservoir of particles and 
an adsorption process takes place rapidly. The direct 
contact of the particles with the intestinal cells through a 
bioadhesive phase is the first step before particle 
absorption. The adhesiveness of the nanosuspensions not 
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only helps to improve bioavailability but also improves 
targeting of the parasites persisting in the GIT. 
CONCLUSION 
The nanosuspension technology have been successfully 
proved to be  useful  for overcoming problem associated 
with poorly soluble drugs or lipophilic drugs insoluble in 
both organic and aqueous media. Large scale production of 
nanosuspension can be employed by media milling and 
high pressure homogenization technique. The recent 
advancement in the work being done related to 
nanosuspension shows that many formulations are being 
developed on a laboratory scale which have a potentially 
important clinical significant to treat diseases. Thus, 
nanosuspension technology is able enough to bring 
enormous immediate benefits and will revolutionize the 
research and practice of medicine in the field of pharmacy. 
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